{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:02:11Z","timestamp":1773842531348,"version":"3.50.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF<jats:sup>V600E<\/jats:sup>-mutated metastatic colorectal cancer (mCRC). Nevertheless, its proven therapeutic efficacy in clinical trials was solely based on partial morphologic responses assessed by CT. To date, only 1 case of complete response assessed by FDG PET\/CT was reported in literature in BRAF<jats:sup>V600E<\/jats:sup>-mutated mCRC, but treated with doublet chemotherapy (FOLFIRI) + cetuximab regimen. We report a complete metabolic response assessed by FDG PET\/CT, maintained over time (13 months) in a 60-year-old woman with BRAF<jats:sup>V600E<\/jats:sup>-mutated mCRC treated by FOLFOXIRI-bevacizumab. This also confirms that FDG PET\/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003190","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:21:53Z","timestamp":1601500913000},"page":"707-708","source":"Crossref","is-referenced-by-count":1,"title":["Complete Metabolic Response Assessed by FDG PET\/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Karim","family":"Amrane","sequence":"first","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"le Pennec","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schick","sequence":"additional","affiliation":[{"name":"Radiotherapy, University Hospital of Brest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Metges","sequence":"additional","affiliation":[{"name":"Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Abgral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib2-20230925","first-page":"1375","article-title":"Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer","volume":"21","year":"2001","journal-title":"Anticancer Res"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12149-012-0609-0","article-title":"The utility of FDG-PET\/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels","volume":"26","year":"2012","journal-title":"Ann Nucl Med"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/s00259-016-3365-x","article-title":"Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study","volume":"26","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/OTT.S180845","article-title":"Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report","volume":"12","year":"2019","journal-title":"OncoTargets Ther"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","year":"2012","journal-title":"Nature"},{"issue":"50","key":"bib10-20230925","first-page":"57","article-title":"FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer","volume":"2014","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/RLU.0000000000002611","article-title":"Complete metabolic response assessed by FDG PET\/CT to FOLFIRI-aflibercept in second-line treatment of metastatic colorectal cancer","volume":"44","year":"2019","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:08:49Z","timestamp":1695622129000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003190","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}